Q-Line Biotech Limited (NSE:QLINE)

Market Cap	13.12B
Revenue (ttm)	3.47B +14.2%
Net Income	557.22M +1.3%
EPS	34.79 -5.1%
Shares Out	23.33M
PE Ratio	16.17
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	342,800
Open	528.95
Previous Close	525.85
Day's Range	527.00 - 568.00
52-Week Range	343.00 - 568.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 17, 2026

About Q-Line Biotech

Q-Line Biotech Limited develops, manufactures, and markets various reagents and consumables in India and internationally. It offers reagent kits, rapid cards, consumables, and point-of-care strips for applications in immunodiagnostics, hematology, molecular diagnostics, clinical chemistry, and others, as well as in vitro testing of human samples, supporting disease prediction, prevention, diagnosis, monitoring, and health status evaluation. The company also provides diagnostic equipment comprising analyzers, point-of-care devices, and other cri...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2010
• Employees: 313
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: QLINE

Financial Performance

In fiscal year 2026, Q-Line Biotech's revenue was 3.47 billion, an increase of 10.73% compared to the previous year's 3.14 billion. Earnings were 557.22 million, an increase of 23.56%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 19, 2026

Data Sources Report a data error